Ofatumumab is a human monoclonal antibody which targets an epitope in the CD20 molecule encompassing parts of the small and large extracellular loops. Ofatumumab is marketed and developed under a co-development and commercialization agreement with Novartis Pharma AG.  

Indication and safety
Ofatumumab is approved as ARZERRA® in certain territories to treat certain chronic lymphocytic leukemia (CLL) indications. 

To report suspected adverse reactions in the U.S., contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Clinical studies
A subcutaneous formulation of ofatumumab is being investigated for use in relapsing multiple sclerosis (RMS). Ofatumumab is being studied in clinical trials, including Investigator Sponsored Studies (ISS).